Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
| Price | $68.51 |
|---|---|
| Market cap | $2.63B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 40-99.5 |
| Beta | 2.05 |
Explore IRON's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.